We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmaceutical companies face a number of challenges in the Vietnamese market,
including low per capita drug spending, at just US$6 in 2003, as well as biased
and poorly enforced regulations.
Leading Japanese drugmaker and US diversified technology company
3M have agreed a joint development and marketing deal for a potential topical
treatment for Human Papillomavirus (HPV) infection and cervical dysplasia.
Groups representing Nigerian health sector workers and officials
appear to have dropped much of their opposition to the government's plans to
launch a new socialised healthcare framework, known as the National Health Insurance
Scheme (NHIS), on May 29.
Belgian chemicals producer Solvay has reported a 4% rise in group
sales to EUR7.88mn (US$10.34bn) for 2004, with net income rising 26% to EUR541mn
(US$709.56mn).
Denmark's Novo Nordisk, which specialises in therapies for blood-related
disorders, has announced encouraging clinical trial results for new stroke therapy
NovoSeven (recombinant coagulation factor VIIa), as published in The New
England Journal of Medicine.
Drug industry associations in Germany have claimed that the country's
generics sector is now ripe for consolidation in the wake of Swiss drugmaker
Novartis' acquisition of Hexal AG.
While criticism of government drug sector policy has come
from across the industry, India's smaller players have been particularly vocal,
vehemently opposing last year's government price-cutting measures.